Generate Biomedicines shares dropped nearly 21% Friday after the company’s $400 million initial public offering, continuing an uneven recovery for biotech stock-market debuts. After a biotech IPO ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

I recently saw a tweet showing how Google has acquired companies over the years and built products around them. Here is the link to the tweet if you want. Now, Google made another announcement: Google ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

The American poet Henry Wadsworth Longfellow called music “the universal language of mankind.” Is that still true when the so-called music is being generated by a probabilistic robot instead of a ...

Seedance 2.0 can take camera movement, visual effects, and motion into account. Seedance 2.0 can take camera movement, visual effects, and motion into account. is a news writer who covers the ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...